Meridian Bioscience (NASDAQ: VIVO) reported Q3 EPS of $0.16, $0.01 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $67.8 million versus the consensus estimate of $66.8 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.